Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 60 Sarcoma 12 CNS 4 Tumor-Agnostic 3 Thoracic 3 Other hematologic neoplasm 2 Head & Neck 2 Gynecologic 2 Plasma cell 1 Other solid neoplasm 1 Myeloid 1 Lymphoid 1 Genitourinary 1 Dermatologic 1 Breast 1

Conditions

Neoplasms 1 Multiple Myeloma 1 Lymphoma, Non-Hodgkin 1

Interventions

Cyclophosphamide 342 Rituximab 304 Vincristine 157 Doxorubicin 154 venetoclax 153 fludarabine 153 Specimen Handling 152 Prednisone 150 Biopsy 122 Magnetic Resonance Spectroscopy 117 obinutuzumab 116 Lenalidomide 109 Dexamethasone 104 Cytarabine 97 ibrutinib 95 Etoposide 92 fludarabine phosphate 87 Methotrexate 84 acalabrutinib 78 Bendamustine Hydrochloride 72 zanubrutinib 71 blinatumomab 63 pembrolizumab 62 CT-P10 60 Gemcitabine 51 Nivolumab 45 glofitamab 44 Calcium Dobesilate 44 Mercaptopurine 43 prednylidene 42

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

regorafenib × Lymphoid × 1 year × Clear all

NCT02693535 2026-05-29

TAPUR

American Society of Clinical Oncology

Phase 2 Recruiting

LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡